Page last updated: 2024-10-29

1-methyl-3-isobutylxanthine and Fragile X Syndrome

1-methyl-3-isobutylxanthine has been researched along with Fragile X Syndrome in 1 studies

1-Methyl-3-isobutylxanthine: A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES
3-isobutyl-1-methylxanthine : An oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively.

Fragile X Syndrome: A condition characterized genotypically by mutation of the distal end of the long arm of the X chromosome (at gene loci FRAXA or FRAXE) and phenotypically by cognitive impairment, hyperactivity, SEIZURES, language delay, and enlargement of the ears, head, and testes. INTELLECTUAL DISABILITY occurs in nearly all males and roughly 50% of females with the full mutation of FRAXA. (From Menkes, Textbook of Child Neurology, 5th ed, p226)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Berry-Kravis, E1
Huttenlocher, PR1

Other Studies

1 other study available for 1-methyl-3-isobutylxanthine and Fragile X Syndrome

ArticleYear
Cyclic AMP metabolism in fragile X syndrome.
    Annals of neurology, 1992, Volume: 31, Issue:1

    Topics: 1-Methyl-3-isobutylxanthine; Adolescent; Adult; Alprostadil; Blood Platelets; Child; Child, Preschoo

1992